MedTrace Logo

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

NCT02618616 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2021-07-20

Study results available
· View outcomes & findings →

Summary

This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10. Following run-in, subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

Conditions

Interventions

DRUG

ZPL-3893787

DRUG

Placebo

Sponsors & Collaborators

  • Ziarco Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Study Director · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-11
Primary Completion
2016-12-22
Completion
2016-12-22
FDA Drug
Yes

Countries

  • Belgium
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618616 on ClinicalTrials.gov